Rockwell Medical, Inc. — FY 2018 Form 10-K
Reporting period: Year ended December 31, 2018; filed March 15, 2019. The filing is an annual report, not a standalone fourth-quarter report. Rockwell Medical manufactures hemodialysis concentrates and is developing renal therapies, particularly Triferic. Concentrates accounted for approximately 96% of 2018 revenue; Triferic had not yet launched commercially in the United States.
Financial performance and position
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $63.4 million | $57.3 million |
| Gross profit (loss) | $(1.6) million | $3.7 million |
| Operating loss | $(32.4) million | $(25.9) million |
| Net loss | $(32.1) million | $(25.9) million |
| Net loss per share | $(0.61) | $(0.51) |
| Cash used in operating activities | $20.4 million | $21.1 million |
- Revenue grew 10.6%, primarily from higher domestic concentrate sales, including increased delivery-cost pass-throughs, and international sales. International sales were 14% of total revenue, versus 12% in 2017.
- Gross margin fell to approximately negative 2.5%, from positive 6.5%. The decline reflected Triferic inventory reserves and write-offs and lower concentrate profitability from distribution costs and pricing.
- At year-end, cash and cash equivalents were $22.7 million, available-for-sale investments were $10.8 million, working capital was $33.6 million, and total liabilities were $25.3 million. The balance sheet reports no borrowings; the filing text does not provide a separate debt-maturity schedule.
- Rockwell raised $21.9 million net in October 2018 by selling 5.54 million common shares, with warrants to purchase up to 2.77 million additional shares. Operating cash use was partly offset by this financing and investment sales.
- Accumulated deficit was $272.4 million. The company reported no income tax expense or benefit and a full valuation allowance against net deferred tax assets.
Material changes and unusual items
- Triferic inventory reserves and write-offs increased by $8.8 million in 2018, including $8.1 million related to Triferic. Year-end Triferic inventory was $8.0 million gross, with $5.8 million reserved; further write-offs were possible depending on launch and sales.
- The company recorded a $0.7 million Calcitriol inventory reserve after deciding U.S. commercialization was not viable at prevailing market prices and production costs.
- Settlement expense was $1.0 million net of insurance reimbursement, relating to disputes with former executives and directors.
- Rockwell restated its first-quarter 2018 financial statements due to errors in inventory-reserve calculations. Management and the auditor identified material weaknesses in financial reporting controls, including finance staffing and segregation of duties, ERP system controls, compensation accounting, and inventory reserves. The auditor issued an adverse opinion on internal control effectiveness, while its opinion on the 2018 financial statements was unqualified.
Outlook, risks and contingencies
- Management expected to launch Dialysate Triferic in the U.S. in the second quarter of 2019. CMS guidance indicated it would be reimbursed within the existing dialysis payment bundle, not through add-on reimbursement, creating adoption and pricing uncertainty.
- Rockwell planned to submit an NDA for I.V. Triferic in the second quarter of 2019 and targeted potential FDA approval and launch in 2020. Management believed it might qualify for separate payment for two years if approved on or after January 1, 2020; eligibility and timing were uncertain. The expected FDA filing fee was approximately $1.3 million.
- The company stated its existing liquidity was insufficient to fund operations and anticipated capital expenditures for the next 12 months from issuance of the financial statements. Additional financing was needed, with no commitments in place. The auditor’s report included a going-concern paragraph citing the $32.1 million net loss, $20.4 million operating cash use and need to raise funds.
- Commercial success depends on Triferic adoption, regulatory approval, reimbursement, product supply and the company’s ability to finance operations. The company also warned that Triferic inventory could expire or require further reserves.
- Customer concentration is significant: DaVita represented 46% of 2018 sales and Baxter 26%; Nipro represented 10%. The DaVita contract was extended only through June 30, 2019, with a longer-term agreement under negotiation.
- The company disclosed an ongoing SEC investigation, consolidated securities class-action litigation alleging misleading statements about Triferic reimbursement and inventory reserves, and other legal matters. The class action was at an early stage; potential loss was not clearly quantified in the filing.
- Other risks include dependence on contract manufacturers, a single-source finished-goods supplier for liquid Dialysate and I.V. Triferic, competition and shipping-cost inflation, and possible repayment of part of Baxter’s upfront fee upon specified trigger events.
Investor verification priorities
- Check subsequent filings for actual Dialysate Triferic launch, adoption, sales, gross margin and inventory use or write-offs.
- Verify I.V. Triferic NDA submission, FDA review outcome, timing, and CMS determination of separate-payment eligibility.
- Assess financing raised after year-end, cash burn, liquidity runway and any resulting dilution or debt obligations.
- Track renewal of the DaVita contract and Baxter distribution performance, pricing and any refund-trigger exposure.
- Review remediation of material weaknesses, any further restatements, and developments in the SEC inquiry and securities litigation.